Revvity Inc. $RVTY Shares Sold by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC

Key Points

• UBS AM sold 10,922 shares of Revvity Inc., decreasing its ownership by 1.4%, leaving it with 781,761 shares valued at approximately $82.7 million.
• Revvity recently reported a quarterly earnings per share (EPS) of $1.18, surpassing analysts' expectations, and experienced a 4.1% year-over-year revenue growth to $720.3 million.
• The company declared a quarterly dividend of $0.07 per share, with a payout ratio of 11.86%, to be paid on November 7th.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC decreased its holdings in Revvity Inc. (NYSE:RVTY - Free Report) by 1.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 781,761 shares of the company's stock after selling 10,922 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.66% of Revvity worth $82,710,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. MBB Public Markets I LLC purchased a new stake in Revvity in the first quarter worth $312,000. United Services Automobile Association purchased a new stake in Revvity in the first quarter worth $301,000. Goldman Sachs Group Inc. increased its stake in Revvity by 45.5% in the first quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company's stock worth $64,232,000 after purchasing an additional 189,871 shares during the period. Parkman Healthcare Partners LLC purchased a new stake in Revvity in the first quarter worth $14,765,000. Finally, Millennium Management LLC increased its stake in Revvity by 102.0% in the first quarter. Millennium Management LLC now owns 69,401 shares of the company's stock worth $7,343,000 after purchasing an additional 35,048 shares during the period. Hedge funds and other institutional investors own 86.65% of the company's stock.

Revvity Stock Up 2.8%

RVTY stock traded up $2.40 during trading on Thursday, reaching $87.79. 1,223,565 shares of the company traded hands, compared to its average volume of 1,150,206. Revvity Inc. has a 12 month low of $81.36 and a 12 month high of $129.50. The business has a 50 day simple moving average of $90.33 and a 200 day simple moving average of $95.46. The company has a market capitalization of $10.19 billion, a price-to-earnings ratio of 37.20, a price-to-earnings-growth ratio of 2.29 and a beta of 0.94. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.75 and a current ratio of 3.33.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings data on Monday, July 28th. The company reported $1.18 earnings per share for the quarter, beating analysts' consensus estimates of $1.14 by $0.04. The company had revenue of $720.28 million for the quarter, compared to the consensus estimate of $711.26 million. Revvity had a return on equity of 7.66% and a net margin of 10.19%.The firm's revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.22 earnings per share. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. On average, equities research analysts anticipate that Revvity Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 17th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Friday, October 17th. Revvity's dividend payout ratio (DPR) is currently 11.86%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Stifel Nicolaus reduced their target price on Revvity from $120.00 to $110.00 and set a "hold" rating on the stock in a research note on Tuesday, July 29th. Bank of America cut their price target on Revvity from $116.00 to $110.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Wall Street Zen lowered Revvity from a "buy" rating to a "hold" rating in a research note on Sunday, August 3rd. Raymond James Financial restated an "outperform" rating and set a $115.00 price target (down previously from $120.00) on shares of Revvity in a research note on Tuesday, July 29th. Finally, Evercore ISI cut their price target on Revvity from $116.00 to $115.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Ten analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $120.07.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.